Get started
PFIZERPFIZERPFIZER

PFIZER

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

4PFE trade ideas

PFE | Time to Load | LONGPfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
NYSE:PFELong
by DivergenceSeeker
1
Pfizer's Quest for GLP-1 Dominance: A Potential Game-ChangerOver the past year, investors have been disappointed with Pfizer as the company's stock experienced a significant decline of 28.8%. This decline can be attributed, in part, to the anticipated drop in sales for Pfizer's COVID-19 vaccine, Comirnaty, and its antiviral treatment, Paxlovid. However, there is an overlooked aspect that investors have failed to recognize: Pfizer's potential as a promising "oasis stock." In contrast, certain companies such as Eli Lilly, Crispr Therapeutics, Microsoft, and Nvidia have garnered significant investor interest since the beginning of 2023, leading to their shares outperforming the broader market. These companies share a common thread of being associated with cutting-edge technologies like artificial intelligence, gene editing, or weight-loss treatments, which have captured the attention of investors. Despite Pfizer's extensive $70 billion spending spree on business development in recent years, the company has struggled to impress Wall Street as of late. This sentiment is reinforced by the fact that Pfizer's stock currently trades at a remarkably undervalued forward-looking earnings yield of 9.2%. This valuation is considerably lower compared to other major pharmaceutical stocks, which have an average earnings yield of 7%, as well as the 10-year U.S. Treasury bond, which yields 3.73%. Fundamentally, investors have not fully embraced Pfizer's compelling value proposition, which revolves around the potential for the company to become a powerhouse in areas such as immunology, rare blood disorders, and cancer treatment by the end of the decade. However, a specific set of clinical assets may soon captivate the market's attention and potentially alter this situation: the oral glucagon-like peptide-1 receptor (GLP-1) agonists, danuglipron and lotiglipron. Danuglipron has recently displayed outstanding results in a mid-stage trial, showing promise as a dual treatment for controlling blood sugar and promoting weight loss in individuals with type 2 diabetes. Pfizer, the pharmaceutical giant, is patiently awaiting the forthcoming mid-stage trial data for lotiglipron before determining which candidate to advance into phase 3 testing. The significance of this lies in the fact that shares of Eli Lilly and Novo Nordisk have experienced substantial upward trends over multiple years, primarily driven by their GLP-1 drugs, tirzepatide and semaglutide, respectively. These innovative medications are expected to generate annual sales of nearly $100 billion due to the increasing prevalence of diabetes and obesity worldwide. While Pfizer is entering the GLP-1 market relatively later, its oral offerings have the potential to effectively compete against injectable drugs like tirzepatide and semaglutide in the long run. Following the release of danuglipron's impressive mid-stage trial data, Cantor Fitzgerald, a financial services firm, has reiterated its price target of $75 per share for Pfizer's stock. This target represents a potential increase of approximately 94% compared to the current stock price. In contrast, most other firms covering Pfizer have adopted a more cautious approach, choosing to wait for phase 3 data from one of the GLP-1 candidates before revising their fair value estimates. This cautious stance is understandable, as mid-stage data often do not reliably predict the outcomes of late-stage trials. Additionally, by the time Pfizer enters the GLP-1 market, tirzepatide and semaglutide may have already established themselves as strong competitors. What does this mean? It suggests that Pfizer possesses a pipeline asset for type 2 diabetes and weight loss that is not fully recognized by the market. It is likely that the pharmaceutical company will have late-stage trial data on either danuglipron or lotiglipron ready for presentation by 2025, paving the way for a commercial launch in 2026. The bottom line is that if Pfizer can develop a GLP-1 asset that surpasses the clinical performance of the current market leaders, it has the potential to create one of the best-selling drugs in history. In such a scenario, Cantor Fitzgerald's ambitious price target, though premature at the moment, may not seem far-fetched in about three years. For investors who are willing to take a more aggressive stance, considering Pfizer as a leading big pharma stock in the near future could prove worthwhile. It's worth noting that the success of Pfizer's GLP-1 assets hinges on the outcome of late-stage trials and their ability to compete effectively with established competitors like tirzepatide and semaglutide. Market dynamics, regulatory approvals, and other factors can also impact the commercial viability of these drugs. Therefore, investors should exercise caution and conduct thorough research before making any investment decisions. Overall, while Pfizer has faced challenges and a decline in stock performance, its potential in the GLP-1 market and other therapeutic areas cannot be overlooked. The company's long-term prospects, driven by innovative treatments and strategic investments, could lead to significant growth and value creation in the coming years.
NYSE:PFE
by FOREXN1
7
BUY: $PFE #18EMA50pivPfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York
NYSE:PFELong
by firdavs_invest
PFE - Buy The Dip or Follow The Trend?When I began research for this post I expected to be giving the bull case for Pfizer. It's the type of stock I like - a household name oozing with quality and prestige, a strong moat, beaten up with strongly bearish sentiment with multiple factors pointing towards recovery, with short term technical support and long term positive fundamental outlook. I like to play the contrarian in the stock market and it often pays well. So what about Pfizer? Well, technically it's RSI oversold (or was on Thursday, before a small bump Friday) on virtually every timeframe from the 1 hour right through to the Weekly. Looking at Measured Moves, something I do regularly, it's down 19 points from it's swing high on Dec 14th 2022, exactly the same as big upswing from Feb 25th to Aug 18th 2021, and just short of the Oct 13th to Dec 20th 2021 swing of 21 points. Note that these 3 swings mentioned are the largest swings in Pfizer history, due to the growth and subsequent crash caused by COVID and the following recovery. We also have the potential for an area of support here, with the area around 36 having seen both support and resistance on a regular basis since 2016, and if we zoom out a year or 2 and look at Volume Profile, depending on where your set your Visible Range you're going to see the point of control landing between 34.5 - 36. Either the current price or just below. So what's the problem? There are a few. "Patent Cliffs" are always an issue for pharmaceutical companies, where after 20 years their patents expire and they have to face competition from generic brands entering the space. Five of Pfizer’s products face patent expiration in the next six years — Eliquis, an anticoagulant medication, Ibrance to treat breast cancer, Xeljanz for arthritis, Xtandi for prostate cancer, and Vyndaqel for transthyretin amyloid cardiomyopathy. Excluding Pfizer's COVID sales, these 5 products respresent 40% of the company's sales. Just this week, William Pao, Pfizer’s chief development officer raised concerns about antitrust regulators cracking down on Mergers and Acquisitions, notably with the blockage of Amgen's $28billion takeover of Horizon. This raises questions about Pfizer's proposed $43billion purchase of Seagen, and whether they too will come under regulator scrutiny. Financially, Pfizer's revenue is expected to meaningfully decline in 2023, mainly due to a drop in COVID-19 related sales. Analysts estimate the revenue to be around $68.1B, a 32% YoY decrease. Pfizer's adjusted EPS for FY23 is expected to be $3.37, down 49% YoY, according to Wall Street estimates. This is a company that since 2000 has traded as low as 12 in 2008, to as high as 61 at the peak of the COVID drug mania. While technically we do look likely to see a relief rally in the near term, this isn't a company I want to be exposed to. There is too much uncertainty, and while it may look cheap on the scale of the last few years, we must bear in mind that those years were drastically inflated due to COVID drugs that are no longer relevent to it's financials. Pfizer is coming back down to earth with a thud, and I think the company belongs in the 27-36 price range until we see more clarity on it's Seagen purchase and how much it's revenues are pilfered by competing generics. No play for me right now on Pfizer. This is the reality of stock analysis - you go down the rabbit hole, and ultimately most stocks are neither a buy or a sell. Just a "wait and see".
NYSE:PFE
by HayeTrading
10
Finding PFE's bottomAccording the CFRA's note, PFE estimates it has about $17B of revenues at risk between 2025 and 2030 due to looming loss of exclusivity. On the other hand, though, we think the pipeline is strong enough to offset these risks and thrive. PFE has 19 drugs in development (including 15 developed in-house) with potential for FWB:20B in revenues by 2030. PFE may not be dependent on more M&A to replenish its portfolio after the Seagen acquisition. The SGX:43B Seagen acquisition, once approved in the late 2023/early 2024 expected time frame, should have a strong contribution to oncology sales. Risks include fiercer competition for the Covid19 vaccine as new players enter the market, new surges of Covid-19 infections reducing hospital visits and new patient starts, unfavorable rulings by the FDA on Pfizer’s drug development candidates in its pipeline, and unexpected generic patent challenges.
NYSE:PFELong
by KhanhC.Hoang
PFE | Recession Proof Stock | Fundamental and Technical analysisNYSE:PFE Pfizer Inc. (PFE) is a leading pharmaceutical company with a diverse portfolio of drugs and products, including vaccines, oncology, and rare disease treatments. The successful rollout of COVID-19 vaccines has been a significant driver of Pfizer's revenue growth, with revenue increasing from HKEX:41 billion in 2020 to HKEX:81 billion in 2021 and $100 billion in 2022. Historically, healthcare demand has been relatively stable during economic downturns, as consumers prioritize their health even in times of financial hardship. While the COVID-19 pandemic has caused unprecedented disruption in the healthcare industry and the broader economy, Pfizer's strong financial position and focus on critical healthcare products and services position the company well for long-term success. Based on my short-term technical analysis, I have a bearish target price of TP1: HKEX:37 and TP2: $34.5 and a bullish target price of TP1: TASE:TASECTORBALANCE and TP2: $46.50. It's important to consider both technical and fundamental factors, as well as the broader economic and industry-specific trends when making investment decisions. Overall, Pfizer's strong revenue growth, diverse portfolio of products, and focus on innovation and development suggest a strong outlook for the company. While the ongoing impacts of the COVID-19 pandemic and related public health measures should be monitored, Pfizer's financial strength and history of innovation position the company well for long-term success in the healthcare industry.
NYSE:PFE
by shkspr
2
PFE Large Cap Pharma increased its dividendPFE just raised its dividend On the chart it has been trending downward as shown also by a down sloping anchored VWAP bands. Price is currently sitting at long term support and two standard deviations below VWAP. It appears to be ready to reverse from the deep undervalued area. In confirmation, teh voume indicator shows moderate increased relative volume compared with March. I see this as a good opportunity to enter a swing long trade or investment. PFE has its increased dividend as a hint to shareholders of increasing earnings also with the next generation of COVID vaccines in the pipeline along with a diversified line of other products. The only thing that will slow PFE down in federal legislation to limit the retail MSRP prices of its products to all consumers including those with no insurance and commercial coverage outside federal programs. PFE is solid as a rock. I see the buy signal.
NYSE:PFELong
by AwesomeAvani
2
$PFE: Trend signal predicts a bottom$PFE has a similar setup to $MRNA here, both are attractive buys from a valuation and technical standpoint here and have been beaten down lately due to the situation with rates, banking woes and negative news about COVID vaccines, COVID lock downs, etc. (a general more negative perception of health measures taken by the US govt since 2020 likely part of the reason for the decline here) The companies still have valuable IP and profitable businesses that can rerate higher over time, specially now that the broad market appears to be trending up long term again. Best of luck! Cheers, Ivan Labrie.
NYSE:PFELong
by IvanLabrie